Exploring the Spectrum: Variability in PD-L1 Over-Expression

Teresa Carmen^*
*Correspondence: Teresa Carmen, Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA, Email:

Introduction

Programmed Death-Ligand 1 (PD-L1) over-expression is a pivotal marker in immunotherapy response, yet its expression variability poses challenges in patient stratification and treatment efficacy prediction. This review delves into the multifaceted landscape of PD-L1 expression, elucidating factors contributing to its heterogeneity across diverse malignancies. We examine the influence of tumor microenvironment, genetic alterations and dynamic changes in PD-L1 expression over the course of treatment. Understanding the intricacies of PD-L1 variability is paramount for refining patient selection strategies and advancing personalized immunotherapy approaches.

Programmed Death-Ligand 1 (PD-L1) has emerged as a pivotal biomarker in cancer treatment, particularly in the realm of immune checkpoint inhibition therapy. Its expression on tumor cells interacts with the Programmed Death 1 (PD-1) receptor on T cells, leading to immune evasion and tumor progression. However, the clinical significance of PD-L1 expression is far from straightforward, with a spectrum of variability observed across different cancers and within individual tumors. Understanding this variability is crucial for optimizing patient stratification and treatment outcomes.

Description

PD-L1 expression exhibits considerable heterogeneity both within and between tumor types. Some tumors display high PD-L1 expression across the majority of cells, while others exhibit low or absent expression. Moreover, PD-L1 expression can be dynamic, influenced by various factors including tumor microenvironment, tumor stage, treatment history and genetic alterations. The tumor microenvironment plays a pivotal role in regulating PD-L1 expression. Inflammatory cytokines, such as interferon-gamma (IFN-γ), released by infiltrating immune cells, can upregulate PD-L1 expression on tumor cells as a mechanism of immune evasion. Conversely, other factors within the tumor microenvironment, such as hypoxia or oncogenic signaling pathways, may downregulate PD-L1 expression [1]. PD-L1 expression often varies according to tumor stage and progression. Early-stage tumors may exhibit lower levels of PD-L1 expression compared to advanced-stage or metastatic tumors. This dynamic regulation of PD-L1 suggests its involvement in tumor immune evasion mechanisms that evolve during cancer progression.

Prior treatments, particularly chemotherapy and radiation therapy, can modulate PD-L1 expression. While some treatments may induce PD-L1 expression as a resistance mechanism, others may downregulate its expression. Understanding the impact of previous therapies on PD-L1 expression is crucial for guiding subsequent treatment decisions. Genomic alterations within tumor cells can also influence PD-L1 expression. For instance, genetic mutations affecting signaling pathways involved in immune regulation, such as the interferon pathway or oncogenic signaling pathways, may impact PD-L1 expression levels. Additionally, genetic alterations within the PD-L1 gene locus itself can affect its transcriptional regulation [2]. The variability in PD-L1 expression has significant clinical implications for cancer diagnosis, prognosis and treatment. PD-L1 expression levels are commonly used as biomarkers to predict response to immune checkpoint inhibitors (ICIs). However, the predictive value of PD-L1 expression is not absolute and responses to ICIs can occur in patients with low or absent PD-L1 expression. Therefore, other biomarkers and clinical factors must be considered alongside PD-L1 expression to optimize patient selection for immunotherapy.

Further research is needed to elucidate the complex regulation of PD-L1 expression and its clinical implications. Integrating multi-omics approaches, including genomics, transcriptomics and proteomics, may provide a comprehensive understanding of the factors influencing PD-L1 expression. Additionally, exploring novel therapeutic strategies targeting PD-L1 regulation mechanisms could enhance the efficacy of immunotherapy and overcome resistance mechanisms [3].

The variability in PD-L1 over-expression is a multifaceted aspect that underpins the complexity of cancer immunotherapy. PD-L1, or programmed death-ligand 1, is a crucial immunomodulatory protein implicated in the evasion of immune surveillance by cancer cells. Its over-expression on tumor cells creates an immunosuppressive microenvironment by binding to the PD-1 receptor on T cells, thereby inhibiting their anti-tumor activity [4].

However, the extent and pattern of PD-L1 expression across different cancer types and even within the same tumor type can vary significantly. This heterogeneity poses challenges in patient stratification for immunotherapy and can influence treatment outcomes. Several factors contribute to the variability in PD-L1 expression. Tumor-intrinsic factors such as genetic alterations, tumor mutational burden and oncogenic signaling pathways can regulate PD-L1 expression levels. Additionally, tumor micro environmental factors such as inflammation, hypoxia and interactions with immune cells can dynamically influence PD-L1 expression. This variability has important implications for the selection of patients who are likely to benefit from PD-L1/PD-1 checkpoint blockade therapy. While PD-L1 expression levels have been utilized as a biomarker for patient selection in some cancers, its predictive value is not absolute and responses to immunotherapy can still occur in patients with low or absent PD-L1 expression.

Moving forward, a deeper understanding of the factors governing PD-L1 expression variability and the intricate interplay between tumor cells and the immune system is essential for optimizing patient selection and treatment strategies in cancer immunotherapy. Integrated approaches combining PD-L1 expression profiling with other biomarkers and genomic analysis hold promise in refining patient stratification and improving clinical outcomes in the era of precision oncology [5].

Conclusion

The variability in PD-L1 expression reflects the intricate interplay between tumor cells, immune cells and the tumor microenvironment. Understanding this variability is essential for harnessing the full potential of immune checkpoint inhibition therapy in cancer treatment. By dissecting the factors influencing PD-L1 expression, we can refine patient stratification strategies and develop personalized therapeutic approaches to improve outcomes for cancer patients across the spectrum of PD-L1 expression.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Cáceres, Diego H., Beatriz L. Gómez, Angela M. Tobón and Tom M. Chiller, et al. "Evaluation of a Histoplasma antigen lateral flow assay for the rapid diagnosis of progressive disseminated histoplasmosis in Colombian patients with AIDS." Mycoses 63 (2020): 139-144.

Google Scholar, Crossref, Indexed at

2. Guadamillas, Marta C., Ana Cerezo and Miguel A. Del Pozo. "Overcoming anoikis–pathways to anchorage-independent growth in cancer." J Cell Sci 124 (2011): 3189-3197.

Google Scholar, Crossref, Indexed at

3. Chi, Weicheng, Lin Ma, Junjie Wu and Mingli Chen, et al. "Deep learning-based medical image segmentation with limited labels." Phys Med Biol 65 (2020): 235001.

Google Scholar, Crossref, Indexed at

4. Fuertes, Gustavo, Diana Giménez, Santi Esteban-Martín and Orlando L. Sánchez-Munoz, et al. "A lipocentric view of peptide-induced pores." Eur Biophys J 40 (2011): 399-415.

Google Scholar, Crossref, Indexed at

5. Favia, Gianfranco, Lorenzo Lo Muzio, Rosario Serpico and Eugenio Maiorano. "Angiosarcoma of the head and neck with intra-oral presentation. A clinico-pathological study of four cases." Oral Oncol 38 (2002): 757-762.

Google Scholar, Crossref, Indexed at